Sacubitril/Valsartan vs Standard Treatment for Preventing Atrial Fibrillation Recurrence After Catheter Ablation in Persistent Atrial Fibrillation Patients With Without Hypertension
Written informed consent obtained prior to any study procedure.
Age between 18 and 79 years, male or female.
Diagnosis of persistent non-valvular atrial fibrillation scheduled for first catheter ablation..
Baseline mean office blood pressure in the non-hypertensive category: Non-elevated BP (100/55 to 120/70 mmHg without antihypertensive drugs) OR Elevated BP (SBP 120-139 mmHg or DBP 70-89 mmHg).
Left ventricular ejection fraction (LVEF) ≥ 40% by echocardiography.
Willingness and ability to comply with scheduled visits and study procedures.
You may not be if
Diagnosed secondary hypertension or hypertension (mean office blood pressure ≥140/90 mmHg or taking ≥2 antihypertensive drugs).
History of symptomatic hypotension, or baseline SBP \<100 mmHg.
Valvular atrial fibrillation (moderate-to-severe mitral stenosis or regurgitation, or mechanical heart valves), cardiomyopathy, cor pulmonale, or coexisting hyperthyroidism or hypothyroidism.
Left atrial anteroposterior diameter \>55 mm.
New York Heart Association (NYHA) functional class IV heart failure, or LVEF \< 40%.
Major cardiovascular events or cerebrovascular diseases within 3 months prior to ablation..
Acute/severe systemic infection within 1 month prior to ablation, or left atrial/appendage thrombus.
Hepatic or renal impairment, defined as alanine aminotransferase or aspartate aminotransferase levels \>2 times the upper limit of normal, or estimated glomerular filtration rate \<30 mL/min/1.73 m2.
Serum potassium \>5.5 mmol/L.
Pregnant or breastfeeding women, psychiatric disorders, or participation in other clinical trials.